Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.
| Autor: | Rahman W; Department of Medicine, University of Maryland Baltimore, Baltimore, Maryland, USA., Conley A; Department of Medicine, University of Maryland Baltimore, Baltimore, Maryland, USA., Silver KD; Department of Medicine, University of Maryland Baltimore, Baltimore, Maryland, USA ksilver@som.umaryland.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMJ case reports [BMJ Case Rep] 2020 Jul 02; Vol. 13 (7). Date of Electronic Publication: 2020 Jul 02. |
| DOI: | 10.1136/bcr-2019-233842 |
| Abstrakt: | Checkpoint inhibitor immunotherapy has revolutionised cancer treatment since its inception. During an inflammatory response, activated cytotoxic T cells expressing programmed cell death protein 1 (PD-1) interact with programmed cell death-ligand 1 (PD-L1) on peripheral tissues to thwart an autoimmune reaction. Cancer cells upregulate PD-L1 expression to evade the immune system and are vulnerable to attack in the presence of PD-1 or PD-L1 checkpoint inhibitors. However, blockade of this pathway also contributes to the unintended side effect of autoimmune endocrinopathies. Atezolizumab, a checkpoint inhibitor against PD-L1, is associated with the rare complication of type 1 diabetes. We present a case of glutamic acid decarboxylase antibody-positive type 1 diabetes developing in a patient with a long-standing history of well-controlled type 2 diabetes following treatment with atezolizumab for metastatic renal cell carcinoma. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|